❤️ Total Artificial Heart Hemodynamic Simulator

Complete Ventricular Replacement — Excising Both Native Ventricles

A total artificial heart (TAH) is fundamentally different from a ventricular assist device (VAD). Where an LVAD leaves the native heart in place and simply augments its output, a TAH surgically removes both native ventricles — leaving only the atria and great vessels — and replaces them with two mechanical pumping chambers. This is a categorically more invasive intervention, reserved for patients whose biventricular failure cannot be managed by supporting a single native ventricle.

• 2: Chambers replaced (both native LV and RV excised)
• Atria: Structures preserved (native atria and great vessels retained)
• 1982: First clinical TAH (Jarvik-7, Barney Clark)
• SynCardia: FDA-approved device (current era) (temporary TAH, bridge to transplant)

Why replace rather than assist

Ventricular assist devices (VADs) work by taking over the pumping work of one failing ventricle while the native heart — including its valves, conduction system, and the other ventricle — remains in place. This is elegant when only one ventricle is critically weak, because the native heart retains partial function and the device simply removes the workload the failing chamber cannot manage.

But in severe biventricular failure — end-stage cardiomyopathy, refractory cardiogenic shock, or a heart destroyed by irreversible ischemic damage — no amount of single-ventricle support restores adequate circulation, because both pumping chambers have failed. A left-sided VAD alone cannot compensate for a right ventricle that cannot move blood into the pulmonary circuit; the reverse is equally true. In these cases, propping up one ventricle while the other continues to fail simply postpones a doomed outcome.

The TAH solution is radical but logically direct: remove both failing ventricles and substitute two independent mechanical pumps, each dedicated to one circuit — systemic and pulmonary — restoring a two-pump-in-series architecture without depending on any native ventricular tissue at all.

A TAH is not a heart "assist" — it is a heart replacement. Once implanted, the patient has no native ventricular function whatsoever; every heartbeat, in both circuits, is generated entirely by the mechanical device.

Surgical anatomy of the exchange

During implantation, surgeons excise both ventricles at the atrioventricular groove, leaving the native atria, the mitral and tricuspid valve annuli region, and the great vessel stumps (aorta and pulmonary artery) intact. Two artificial ventricles are then anastomosed: one connects the left atrium to the aorta (replacing the native LV), and one connects the right atrium to the pulmonary artery (replacing the native RV). Each artificial ventricle contains its own set of inflow and outflow valves — typically mechanical tilting-disc or bileaflet valves — that enforce unidirectional flow exactly as native atrioventricular and semilunar valves once did.

Because the device fully substitutes for both ventricles, TAH implantation requires more extensive surgical dissection and cardiopulmonary bypass time than VAD implantation, and it is technically irreversible — there is no native ventricle left to recover or fall back on if the device fails.

Pneumatic and Hydraulic Drive — How an External Console Powers the Artificial Ventricles

Each artificial ventricle in a pneumatic TAH is built around a flexible diaphragm that separates a blood-contacting chamber from an air-contacting chamber. An external drive console delivers alternating pulses of compressed air (or, in hydraulic designs, pressurized fluid) through percutaneous drivelines, displacing the diaphragm to eject blood during "systole" and allowing it to retract during "diastole." The console — not any biological tissue — is the actual power source of every heartbeat.

• Air or fluid: Drive medium (pneumatic vs. hydraulic actuation)
• 2 per chamber: Driveline count (ejection + venting lines)
• Console or wearable: Console type (bedside unit or portable driver)
• Systole / Diastole: Cycle components (ejection then passive fill)

The diaphragm pump cycle

Each artificial ventricle chamber is divided by a flexible, biocompatible diaphragm (typically a segmented polyurethane membrane) into two compartments: a blood chamber on one side and a pneumatic (or hydraulic) drive chamber on the other.

Ejection (systole): the drive console delivers a pulse of compressed air into the drive chamber. Rising air pressure pushes the diaphragm toward the blood chamber, compressing it and forcing blood out through the outflow valve into the aorta or pulmonary artery. Peak drive pressures are tuned so that ejection is complete and forceful, analogous to native ventricular contraction.

Filling (diastole): the console vents the drive chamber pressure and, in most designs, applies a brief vacuum. The diaphragm retracts, the blood chamber expands, and blood is drawn in through the inflow valve from the atrium — passive filling assisted by mild negative pressure, standing in for ventricular relaxation.

This alternating ejection/filling sequence repeats continuously at the programmed beat rate, with the two artificial ventricles (systemic and pulmonary) typically driven with a coordinated, near-simultaneous timing so that right- and left-sided output stay balanced.

Pneumatic TAH systems require the drive console to be tethered to the patient via percutaneous lines — a major quality-of-life constraint. Fully implantable hydraulic and electric designs aim to eliminate this tether, but at the cost of added mechanical complexity.

Console control and drive parameters

The external drive console is a programmable pneumatic (or hydraulic) compressor-vacuum system. Clinicians set several parameters that together determine device output:

• Beat rate (beats/min): how frequently the ejection-fill cycle repeats • Drive pressure: the peak air pressure applied during ejection, which determines how completely the diaphragm empties the blood chamber (and thus effective stroke volume) • Vacuum level: the negative pressure applied during filling, which affects how quickly and completely the chamber refills before the next ejection • Systolic duration (percent of cycle spent ejecting vs. filling)

Because both artificial ventricles are driven from the same console, the systemic and pulmonary outputs can be balanced deliberately — a capability the native heart achieves automatically through Frank-Starling mechanics and vascular resistance feedback, but which the TAH console must approximate through fixed pressure and timing settings.

Fixed-Rate vs Physiologic Output — Titrating a Machine That Cannot Autoregulate

A native heart continuously adjusts its output beat-to-beat: heart rate rises with exertion via sympathetic stimulation, stroke volume rises with venous return via the Frank-Starling mechanism, and baroreceptor reflexes fine-tune blood pressure within seconds. A TAH has none of this innate feedback. Its beat rate and stroke volume are whatever the drive console is set to deliver — adjustable by a clinician, but not self-adjusting in response to the patient's real-time physiologic demand.

• Rate + Volume: Adjustable parameters (set manually on console)
• 4–8 L/min: Typical target output (resting adult cardiac output range)
• No: Autoregulation present? (lacks native autonomic feedback)
• Clinician titration: Adjustment method (periodic manual reassessment)

Cardiac output as a simple product

Device cardiac output is calculated the same way native cardiac output is: beat rate multiplied by stroke volume. For a TAH:

Cardiac output (L/min) = beat rate (beats/min) × stroke volume (mL) / 1000

Unlike the native heart, where stroke volume varies breath-to-breath and beat-to-beat with preload, afterload, and contractility, a TAH's stroke volume is essentially fixed by the chamber's mechanical fill/eject characteristics at a given drive pressure and vacuum setting. This means TAH output is far more "digital" than native cardiac output: within the operating range, output is a near-deterministic function of two console settings rather than a continuously self-adjusting physiologic variable.

Clinicians must therefore proactively estimate what output a given patient needs — based on body size, activity level, and clinical status — and dial in a rate and stroke volume combination expected to meet it, then reassess and retitrate periodically rather than relying on the device to sense and respond on its own.

The consequences of a mismatch

Because the TAH cannot sense metabolic demand, both under- and over-titration carry real consequences:

Under-titration (rate or stroke volume too low): cardiac output falls below what tissues require. Patients experience fatigue, reduced exercise tolerance, and in severe cases hypoperfusion — pallor, cool extremities, confusion, or rising lactate. The clinical response is to increase rate and/or stroke volume.

Over-titration (rate or stroke volume too high): cardiac output exceeds physiologic need. This can produce excessive systemic pressures, unnecessary mechanical wear, and — because inflow to each artificial ventricle depends on adequate venous return — a chamber driven faster than it can passively refill may under-fill and eject less effectively than intended, an effect analogous to native tachycardia curtailing diastolic filling time.

Because there is no autonomic reflex to catch either extreme automatically, the entire burden of matching supply to demand falls on periodic clinical reassessment — one of the central practical differences between living with a TAH and living with a native heart.

Some modern TAH designs incorporate simple automatic "physiologic" response modes — for instance, altering rate based on filling pressure sensors — narrowing but not eliminating the gap with native autoregulation. Most clinically deployed devices, however, remain fundamentally rate- and stroke-volume-fixed until a clinician manually retitrates them.

Who Receives a Total Artificial Heart — Indication and Decision Pathway

Because TAH implantation is irreversible and more invasive than VAD placement, it is reserved for a narrow and severe indication: biventricular failure that a single-ventricle LVAD cannot adequately support, most commonly deployed as a bridge to transplant rather than permanent destination therapy, given current constraints on device durability, size, and the requirement for external or wearable drive equipment.

• Biventricular failure: Primary indication (both ventricles irreversibly failing)
• Bridge to transplant: Typical use case (rather than destination therapy)
• LVAD: Alternative tried first (when single-ventricle support suffices)
• Durability / portability: Limiting factor (console tether, device lifespan)

The decision pathway from single- to dual-ventricle support

Clinical decision-making generally follows an escalating pathway:

1. Assess ventricular function: is one ventricle failing while the other retains adequate function, or are both ventricles failing together?

2. If failure is isolated to the left ventricle (the far more common scenario — e.g., ischemic or dilated cardiomyopathy): an LVAD is typically the first-line mechanical option, since it directly addresses the dominant systemic pumping deficit while leaving a functioning right ventricle to independently manage the pulmonary circuit.

3. If right ventricular failure develops or persists despite LVAD support (a recognized complication after LVAD implantation), or if biventricular failure is present from the outset — for example, in restrictive/infiltrative cardiomyopathy, extensive biventricular infarction, fulminant myocarditis, or a heart too diffusely diseased to support any single-ventricle approach — an LVAD alone will be insufficient. This is the point at which TAH implantation becomes the appropriate escalation.

4. TAH implantation removes both failing ventricles at once, eliminating the biventricular mismatch problem entirely rather than attempting to correct it indirectly.

Bridge to transplant, not destination

Because currently available TAH systems typically require a percutaneous driveline tethered to an external or wearable console, and because device components have a finite mechanical service life, TAH implantation is most often used as a bridge to transplant — sustaining circulation for months while a patient awaits a suitable donor heart — rather than as permanent, lifelong destination therapy.

This distinguishes the clinical framing of TAH from some contemporary continuous-flow LVADs, which have matured to the point of being used as destination therapy in patients ineligible for transplant. TAH candidates are, by definition, patients whose disease is too advanced for LVAD bridging or destination use, but who remain reasonable transplant candidates once stabilized on total mechanical circulatory support.

The indication logic can be summarized as a single decision rule: if a patient's circulatory failure can be adequately corrected by supporting one ventricle, an LVAD is used; if it cannot — because both ventricles have failed — a TAH replaces both, almost always as a temporizing measure before transplantation.

Hemodynamic Monitoring — Externally Performing What Autoregulation Once Did

With no native ventricular tissue and no autonomic feedback loop, sustaining a TAH patient safely requires ongoing external monitoring of the same variables the body once regulated automatically: how much blood the device is moving, how well each chamber is filling, and how much physical exertion the current settings can support. Adjustments are made deliberately by the care team, in principle mirroring native cardiac output regulation but executed manually rather than reflexively.

• Cardiac output: Core monitored variable (device rate × stroke volume)
• Chamber fill volume: Filling assessment (proxy for venous return adequacy)
• 4–8 L/min: Target resting range (typical adult physiologic range)
• Ongoing: Adjustment cadence (reassessed with activity and status)

What is tracked and why

Because the TAH cannot sense the patient's metabolic state, clinicians substitute a structured monitoring routine for the missing physiologic feedback loop:

• Calculated cardiac output: derived directly from programmed beat rate and stroke volume (output = rate × stroke volume / 1000), cross-checked where possible against clinical perfusion indicators (mentation, capillary refill, urine output, lactate).

• Filling behavior: whether each artificial ventricle fills completely before every ejection. Incomplete filling — often from inadequate venous return, high pulmonary vascular resistance, or a beat rate too fast to allow full diastolic fill time — signals that current settings may not be sustainable and lowers effective output below the calculated value.

• Systemic and pulmonary pressures: analogous to native blood pressure and central venous/pulmonary pressures, tracked to confirm the two circuits remain balanced against each other.

• Patient activity level and reported exertional tolerance: the ultimate real-world check on whether current device output is sufficient for the patient's daily needs, feeding back into rate/stroke volume adjustments.

Closing the loop manually

The clinical workflow effectively recreates, step by step and by hand, what native autoregulation performs continuously and automatically:

1. Estimate demand — from body size, clinical status, and desired activity level 2. Set rate and stroke volume — to produce a calculated output expected to meet that demand 3. Monitor outcome — perfusion indicators, filling behavior, and patient-reported exertional tolerance 4. Retitrate — increase rate or stroke volume if output proves inadequate for the patient's needs; reduce if output is excessive relative to need or is causing strain

This cycle never runs autonomously; it requires periodic clinical reassessment for the life of the device. It is one of the clearest illustrations of what mechanical circulatory support does and does not replace: the pump itself is well within engineering reach, but the regulatory intelligence of the native cardiovascular system — the instantaneous, self-correcting matching of supply to demand — remains a task performed by the care team, not the machine.

This is precisely the logic the simulator's control panel reproduces: adjusting beat rate and stroke volume changes calculated cardiac output, which is then classified against a normal physiologic target range to recommend whether settings should be increased, maintained, or reduced — a simplified stand-in for real bedside titration.